CD8A and myeloid sarcoma: In addition, a profound increase in the percentage of responding CD8+ Tcm cells was observed in MS-OCR patients after the first vaccination, of which substantially more cells co-expressed three to four dynamic markers following first vaccination compared to HCs (Figure 5f and Figure 5—figure supplement 1e), which is indicative of a high-quality recall response.